$249.17
1.55% yesterday
NYSE, Jan 06, 10:00 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Stock price

$249.19
-0.85 0.34% 1M
-7.22 2.82% 6M
+8.32 3.45% YTD
+14.10 6.00% 1Y
+40.30 19.29% 3Y
+35.98 16.88% 5Y
+197.79 384.81% 10Y
+230.76 1,252.09% 20Y
NYSE, Closing price Tue, Jan 06 2026
+3.83 1.56%

New AI Insights on ResMed Insights AI Insights on ResMed

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$36.4b
Enterprise Value
$35.7b
Net debt
positive
Cash
$1.4b
Shares outstanding
145.9m
Valuation (TTM | estimate)
P/E
25.5 | 22.7
P/S
6.9 | 6.4
EV/Sales
6.8 | 6.3
EV/FCF
20.3
P/B
5.9
Dividends
DPS
$2.12
Yield 1Y | 5Y
0.9% | 0.8%
Growth 1Y | 5Y
10.4% | 6.3%
Payout 1Y | 3Y
22.3% | 25.8%
Increased
4 Years
Financials (TTM | estimate)
Revenue
$5.3b | $5.7b
EBITDA
$1.8b | $2.2b
EBIT
$1.8b | $2.0b
Net Income
$1.4b | $1.6b
Free Cash Flow
$1.8b
Growth (TTM | estimate)
Revenue
9.4% | 9.9%
EBITDA
23.4% | 27.6%
EBIT
24.2% | 19.8%
Net Income
29.2% | 14.4%
Free Cash Flow
30.4%
Margin (TTM | estimate)
Gross
60.1%
EBITDA
34.4% | 39.1%
EBIT
33.5%
Net
27.4% | 28.4%
Free Cash Flow
33.4%
Financial Health
Equity Ratio
73.0%
Return on Equity
23.5%
ROCE
25.0%
ROIC
22.9%
Debt/Equity
0.1
More
EPS
$9.8
FCF per Share
$12.0
Short interest
8.3%
Employees
10k
Rev per Employee
$520.0k
Show more

Is ResMed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

ResMed Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a ResMed forecast:

17x Buy
68%
7x Hold
28%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a ResMed forecast:

Buy
68%
Hold
28%
Sell
4%

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
5,257 5,257
9% 9%
100%
- Direct Costs 2,100 2,100
3% 3%
40%
3,157 3,157
14% 14%
60%
- Selling and Administrative Expenses 1,011 1,011
8% 8%
19%
- Research and Development Expense 339 339
9% 9%
6%
1,807 1,807
23% 23%
34%
- Depreciation and Amortization 46 46
1% 1%
1%
EBIT (Operating Income) EBIT 1,761 1,761
24% 24%
33%
Net Profit 1,438 1,438
29% 29%
27%

In millions USD.

Don't miss a Thing! We will send you all news about ResMed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ResMed Stock News

Neutral
GlobeNewsWire
19 days ago
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA.
Positive
Seeking Alpha
29 days ago
I track a custom universe of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities based on valuation and forward return potential. 28 of these stocks currently offer estimated future returns of at least 10%, with 18 appearing potentially undervalued per my Free Cash Flow model. Top-ranked names like ResMed, Mastercard, and MSCI combine strong projected ...
Neutral
GlobeNewsWire
30 days ago
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Settings (PTCS), to be marketed as Smart Comfort. Smart Comfort is the first FDA-cleared AI-enabled medical d...
More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office United States
CEO Mick Farrell
Employees 9,980
Founded 1989
Website www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today